119 filings
Page 4 of 6
8-K
qbw s5rr9d
19 Mar 19
Other Events
9:08pm
8-K
j60htszyqw
27 Feb 19
Sage Therapeutics Announces Closing of $575 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
4:05pm
8-K
y92k3z9lqgq 7z6ae0o9
27 Feb 19
Sage Therapeutics Announces Proposed Public Offering of Common Stock
8:08am
8-K
t6srm e0i1b
19 Feb 19
Sage Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress
7:07am
8-K
2wxtj de43f5x46
23 Jan 19
Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors
5:03pm
8-K
oqka7tudjgx8cvh6 xhv
7 Jan 19
Regulation FD Disclosure
7:30am
8-K
dwfp 7siu8jmf
20 Nov 18
Sage Therapeutics Receives Notification of PDUFA Extension
4:06pm
8-K
7tp3hzduc9j1z
6 Nov 18
Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
6:46am
8-K
0mejl0cgov
2 Nov 18
Other Events
5:26pm
8-K
5iu44b8in ot
7 Aug 18
Results of Operations and Financial Condition
7:30am
8-K
9clnrd0ats
14 Jun 18
Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration
12:00am
8-K
jr4iy 8k53
12 Jun 18
Sage Announces Pivotal Phase 3 Trial Status forSAGE-217 in Major Depressive Disorder and Postpartum
7:30am
8-K
gqvob9mpu1ud1m2
8 Jun 18
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
6gtcknwivdcooz6x
30 May 18
Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression
7:30am
8-K
jhohqm58qsba5f1s hj
3 May 18
Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline
12:00am
8-K
ggyyd01
22 Feb 18
Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update
12:00am
8-K
bxk6ek8x ougy
13 Feb 18
Other Events
12:00am
8-K
b1r1bnr
9 Feb 18
Sage Therapeutics Announces Proposed Public Offering of Common Stock
12:00am
8-K
5oicn
7 Feb 18
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217
12:00am
8-K
alam4i5da4 h8px4
7 Feb 18
Regulation FD Disclosure
12:00am